Clinical Trials
28 trialsA Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
SEED Therapeutics, Inc.
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
M.D. Anderson Cancer Center
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
National Cancer Institute (NCI)
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Kivu Bioscience Inc.
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
Agenus Inc.
A Study of MGC026 in Participants With Advanced Solid Tumors
MacroGenics
ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
UNC Lineberger Comprehensive Cancer Center
SLV-154 Treatment of Metastatic Solid Tumors
Solve Therapeutics
Endoxifen in Adults With Hormone Receptor Positive Solid Tumors
National Institutes of Health Clinical Center (CC)
(VELA) Study of BLU-222 in Advanced Solid Tumors
Blueprint Medicines Corporation
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
Numab Therapeutics AG
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
NextPoint Therapeutics, Inc.
TAS-116 Plus Palbociclib in Breast and Rb-null Cancer
Brown University
DUET-3
Xencor, Inc.
A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
Prelude Therapeutics
Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies
Celon Pharma SA
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Corvus Pharmaceuticals, Inc.
A Study Evaluating MM-310 in Patients With Solid Tumors
Merrimack Pharmaceuticals
Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer
Masonic Cancer Center, University of Minnesota
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Regeneron Pharmaceuticals
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Regeneron Pharmaceuticals
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
Rutgers, The State University of New Jersey
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
National Cancer Institute (NCI)
Topotecan in Treating Patients With Gynecologic Cancer That Cannot Be Removed by Surgery
Case Comprehensive Cancer Center
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
National Institutes of Health Clinical Center (CC)
PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer
National Cancer Institute (NCI)
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.
Mannkind Corporation